Spikevax 2026-2027 Injectable Product
RxNorm 2750240

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2750240 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Spikevax 2026-2027 Injectable Product.

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDG
Spikevax 2026-2027 Injectable Product
AUI:13080530
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDGPrescribable

Semantic Branded Dose Form Group (SBDG):
Spikevax 2026-2027 Injectable Product
(Atom ID: 13080530)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Spikevax 2026-2027 Injectable Product
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2750240
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
13080530
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDG
Semantic Branded Dose Form Group (Brand Name + Dose Form Group)
Source Code
2750240
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_261102F
The specific version of the vocabulary provided by the source.
Update Date
November 02, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AVAILABLE STRENGTH
0.1 MG/ML (expressed as SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 XFG (JN.1))
Available drug strengths listed in the order of ingredients from the drug